| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-51 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2010-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71b8972085e972336d3fc3ed459c3c59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_912ba3e5500f4da757ac1e125a6f5777
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1861eca1e1f1d16e2421b7d4d9f74aaa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b92c3d55c976d195416c75d362de3ec1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36a4b7cb61a6d52bb49f9e5e49889b17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f84916c02972d1c1fffbdca2c3e2645d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22432117fba03a448c6f609faf4d311d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc52528696b344f82ef37fd4f1a68ef2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7abc0cb2c7c79295b4ad678357f877f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_482340f0b871427de038993bacf10242
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30e5b37c6bb2f0f80e67d06b3ce40c3e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2aa78422e02e5c999c7a45cf15f59dfd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55a6e625258c712ff2e767ac01528b26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58c6b7d011248193bb196f5aa96a4e95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57cc72ea3d18097fbd6a8b06b2a75ec6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7878f997756d86a5e4dcddf011a3168 |
| publicationDate |
2011-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2784498-A1 |
| titleOfInvention |
Novel antagonist antibodies and their fab fragments against gpvi and uses thereof |
| abstract |
FR2009/113 PCT PATENT APPLICATION TITLE Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof SANOFI-AVENTIS ABSTRACT The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab. The invention concerns a method for prevention of platelet activation when an anti-GP VI Fab is used. |
| priorityDate |
2009-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |